Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Quan Zhou, Lu-Shan Yu & Su Zeng. (2014) Stereoselectivity of chiral drug transport: a focus on enantiomer–transporter interaction. Drug Metabolism Reviews 46:3, pages 283-290.
Read now
Read now
Katherine S. Fenner, Hannah M. Jones, Mohammed Ullah, Sarah Kempshall, Maurice Dickins, Yurong Lai, Paul Morgan & Hugh A. Barton. (2012) The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 42:1, pages 28-45.
Read now
Read now
Articles from other publishers (46)
Joseph PiscitelliMina NikanjamEdmund V. Capparelli, Chelsea L. BlaqueraScott R. Penzak, Thomas D. Nolin, Mary F. Paine & Joseph D. Ma. (2023) Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach. Therapeutic Drug Monitoring 45:4, pages 539-545.
Crossref
Crossref
Ji-Hun Jang, Seung-Hyun Jeong & Yong-Bok Lee. (2023) Establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and exploration of dosing regimens through simulation. Journal of Pharmaceutical Investigation 53:3, pages 427-441.
Crossref
Crossref
Liqiao Li, Runqiu Liu, Cong Peng, Xiang Chen & Jie Li. (2022) Pharmacogenomics for the efficacy and side effects of antihistamines. Experimental Dermatology 31:7, pages 993-1004.
Crossref
Crossref
Karelle Ménochet, Hugues Chanteux, Jamie Henshall, Jean‐Marie Nicolas, Sara Wright, Judith van Asperen & Anna‐Lena Ungell. 2022. Oral Drug Delivery for Modified Release Formulations. Oral Drug Delivery for Modified Release Formulations
39
64
.
Samantha Medwid, Hayley R. Price, Daniel P. Taylor, Jaymie Mailloux, Ute I. Schwarz, Richard B. Kim & Rommel G. Tirona. (2021) Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. Frontiers in Pharmacology 12.
Crossref
Crossref
Youmna Ali, Tahiatul Shams, Ke Wang, Zhengqi Cheng, Yue Li, Wenying Shu, Xiaofeng Bao, Ling Zhu, Michael Murray & Fanfan Zhou. (2020) The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions. Chinese Medicine 15:1.
Crossref
Crossref
Melissa S. Unger, Lena Schumacher, Thomas Enzlein, David Weigt, Maciej J. Zamek-Gliszczynski, Matthias Schwab, Anne T. Nies, Gerard Drewes, Sandra Schulz, Friedrich B. M. Reinhard & Carsten Hopf. (2020) Direct Automated MALDI Mass Spectrometry Analysis of Cellular Transporter Function: Inhibition of OATP2B1 Uptake by 294 Drugs. Analytical Chemistry 92:17, pages 11851-11859.
Crossref
Crossref
Leonardo Pinto, Fernanda de Lima Moreira, Glauco Henrique Balthazar Nardotto, Ricardo Carvalho Cavalli, Elaine Christine Dantas Moisés, Geraldo Duarte & Vera Lucia Lanchote. (2020) Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. Pharmaceutical Research 37:7.
Crossref
Crossref
Jiro Ogura, Hiroaki Yamaguchi & Nariyasu Mano. (2020) Stimulatory effect on the transport mediated by organic anion transporting polypeptide 2B1. Asian Journal of Pharmaceutical Sciences 15:2, pages 181-191.
Crossref
Crossref
Samantha Medwid, Mandy M.J. Li, Michael J. Knauer, Kathleen Lin, Sara E. Mansell, Crystal L. Schmerk, Catherine Zhu, Katelyn E. Griffin, Mohamed D. Yousif, George K. Dresser, Ute I. Schwarz, Richard B. Kim & Rommel G. Tirona. (2019) Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metabolism and Disposition 47:8, pages 832-842.
Crossref
Crossref
Yumiko Akamine, Norio Yasui-Furukori & Tsukasa Uno. (2019) Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. Current Drug Metabolism 20:2, pages 124-129.
Crossref
Crossref
Savannah J. McFeely, Lanxiang Wu, Tasha K. Ritchie & Jashvant Unadkat. (2019) Organic anion transporting polypeptide 2B1 – More than a glass-full of drug interactions. Pharmacology & Therapeutics 196, pages 204-215.
Crossref
Crossref
Stefan Oswald. (2019) Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacology & Therapeutics 195, pages 39-53.
Crossref
Crossref
Yaru Xue, Chenhui Ma, Imad Hanna & Guoyu Pan. 2019. Drug Transporters in Drug Disposition, Effects and Toxicity. Drug Transporters in Drug Disposition, Effects and Toxicity
361
405
.
Robert Gharavi & Hazem E. Hassan. 2018. Genomics-Driven Healthcare. Genomics-Driven Healthcare
133
175
.
Tae-Eun Kim, Dongseong Shin, Namyi Gu, Byung Hwa Jung, Jayoun Kim, Young Min Cho, Kyung-Sang Yu & Joo-Youn Cho. (2017)
The Effect of Genetic Polymorphisms in
SLCO2B1
on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein
. Basic & Clinical Pharmacology & Toxicology 121:3, pages 195-201.
Crossref
Crossref
Jingjing Yu, Zhu Zhou, Jessica Tay-Sontheimer, René H. Levy & Isabelle Ragueneau-Majlessi. (2017) Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Journal of Pharmaceutical Sciences 106:9, pages 2312-2325.
Crossref
Crossref
Yan Li, Jezrael Revalde & James W. Paxton. (2017) The effects of dietary and herbal phytochemicals on drug transporters. Advanced Drug Delivery Reviews 116, pages 45-62.
Crossref
Crossref
Fei Li, Karyn D Howard & Michael J Myers. (2017) Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers. Journal of Pharmacy and Pharmacology 69:3, pages 274-284.
Crossref
Crossref
Yogita A. Ghodke-Puranik & Jatinder K. Lamba. 2017. Innovative Approaches in Drug Discovery. Innovative Approaches in Drug Discovery
195
234
.
Cheynne McLean, Aze Wilson & Richard B. Kim. (2016) Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. The Journal of Clinical Pharmacology 56, pages S40-S58.
Crossref
Crossref
Miriam G. Mooij, Anne T. Nies, Catherijne A. J. Knibbe, Elke Schaeffeler, Dick Tibboel, Matthias Schwab & Saskia N. de Wildt. (2015) Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clinical Pharmacokinetics 55:5, pages 507-524.
Crossref
Crossref
Yumiko Akamine, Masatomo Miura, Hisakazu Komori, Ikumi Tamai, Ichiro Ieiri, Norio Yasui-Furukori & Tsukasa Uno. (2015) The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. Drug Metabolism and Pharmacokinetics 30:5, pages 352-357.
Crossref
Crossref
Yumiko Akamine. (2015) Determinants of the Stereoselective Pharmacokinetics of Fexofenadineフェキソフェナジンの立体選択的体内動態とその規定因子の解析. YAKUGAKU ZASSHI 135:3, pages 473-481.
Crossref
Crossref
Y. Akamine, M. Miura, N. Yasui-Furukori, I. Ieiri & T. Uno. (2015) Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers. Journal of Clinical Pharmacy and Therapeutics 40:1, pages 98-103.
Crossref
Crossref
Kazuyuki Numakura, Hideaki Kagaya, Ryohei Yamamoto, Naoki Komine, Mitsuru Saito, Tsuruta Hiroshi, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi, Takenori Niioka, Masatomo Miura & Shigeru Satoh. (2015) Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation. Disease Markers 2015, pages 1-8.
Crossref
Crossref
Yumiko Akamine, Masatomo Miura, Hisakazu Komori, Shun Saito, Hiroyuki Kusuhara, Ikumi Tamai, Ichiro Ieiri, Tsukasa Uno & Norio Yasui-Furukori. (2014) Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. European Journal of Clinical Pharmacology 70:9, pages 1087-1095.
Crossref
Crossref
Chiho OnoHironori Kikkawa, Akiyuki Suzuki, Misaki Suzuki, Yuichi Yamamoto, Katsuomi Ichikawa, Masato Fukae & Ichiro Ieiri. (2013) Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. Pharmacogenomics 14:14, pages 1745-1764.
Crossref
Crossref
Margarida Estudante, José G. Morais, Graça Soveral & Leslie Z. Benet. (2013) Intestinal drug transporters: An overview. Advanced Drug Delivery Reviews 65:10, pages 1340-1356.
Crossref
Crossref
Kyoung-Ah Kim, Hye-Mi Lee, Hyun-Jin Joo, In-Bae Park & Ji-Young Park. (2013)
Effects of polymorphisms of the
SLCO2B1
transporter gene on the pharmacokinetics of montelukast in humans
. The Journal of Clinical Pharmacology, pages n/a-n/a.
Crossref
Crossref
Bernard Testa, Giulio Vistoli, Alessandro Pedretti & John Caldwell. (2013) Organic Stereochemistry. Part 5. Helvetica Chimica Acta 96:5, pages 747-798.
Crossref
Crossref
E Ch Yiannakopoulou. (2012) Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. The Pharmacogenomics Journal 13:2, pages 105-109.
Crossref
Crossref
Anne T. Nies. 2013. Pharmacogenomics of Human Drug Transporters. Pharmacogenomics of Human Drug Transporters
345
364
.
Kenta YoshidaKazuya MaedaYuichi Sugiyama. (2013) Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms. Annual Review of Pharmacology and Toxicology 53:1, pages 581-612.
Crossref
Crossref
Inna Y. Gong & Richard B. Kim. (2013) Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metabolism and Pharmacokinetics 28:1, pages 4-18.
Crossref
Crossref
Atsuko Tomaru, Mariko Takeda-Morishita, Hirokazu Banba & Kozo Takayama. (2013) Analysis of the Pharmacokinetic Boosting Effects of Ritonavir on Oral Bioavailability of Drugs in Mice. Drug Metabolism and Pharmacokinetics 28:2, pages 144-152.
Crossref
Crossref
Hiroyuki Kusuhara, Kenta Yoshida & Yuichi Sugiyama. 2013. Transporters in Drug Development. Transporters in Drug Development
67
97
.
Yoshihisa Shitara, Kazuya Maeda, Kazuaki Ikejiri, Kenta Yoshida, Toshiharu Horie & Yuichi Sugiyama. (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharmaceutics & Drug Disposition 34:1, pages 45-78.
Crossref
Crossref
Kohei Togami, Yuka Tosaki, Sumio Chono, Kazuhiro Morimoto, Masataka Hayasaka & Hitoshi Tada. (2013) Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells. Journal of Pharmacy and Pharmacology 65:1, pages 22-29.
Crossref
Crossref
Hiroyuki Kusuhara, Hidetoshi Furuie, Akihiro Inano, Akihiro Sunagawa, Saiko Yamada, Chunyong Wu, Shinya Fukizawa, Nozomi Morimoto, Ichiro Ieiri, Mariko Morishita, Kiminobu Sumita, Hiroshi Mayahara, Takuya Fujita, Kazuya Maeda & Yuichi Sugiyama. (2012) Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. British Journal of Pharmacology 166:6, pages 1793-1803.
Crossref
Crossref
Kei Suzuki, Yoshihisa Shitara, Kousuke Fukuda & Toshiharu Horie. (2012) Long-Lasting Inhibition of the Intestinal Absorption of Fexofenadine by Cyclosporin a in Rats. Journal of Pharmaceutical Sciences 101:7, pages 2606-2615.
Crossref
Crossref
Ikumi Tamai. (2012) Oral drug delivery utilizing intestinal OATP transporters. Advanced Drug Delivery Reviews 64:6, pages 508-514.
Crossref
Crossref
Megan Roth, Amanda Obaidat & Bruno Hagenbuch. (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British Journal of Pharmacology 165:5, pages 1260-1287.
Crossref
Crossref
Yumiko Akamine, Masatomo Miura, Norio Yasui-Furukori, Midori Kojima & Tsukasa Uno. (2012) Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. British Journal of Clinical Pharmacology 73:3, pages 478-481.
Crossref
Crossref
Ming Yao & Nuggehally R. Srinivas. (2012) Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. Biomedical Chromatography, pages n/a-n/a.
Crossref
Crossref
Takeo Nakanishi & Ikumi Tamai. (2012) Genetic Polymorphisms of OATP Transporters and Their Impact on Intestinal Absorption and Hepatic Disposition of Drugs. Drug Metabolism and Pharmacokinetics 27:1, pages 106-121.
Crossref
Crossref